Frazier Life Sciences Management, L.P.
CIK 1892134
13F filing for Q2 2026・No. 969
- Holdings
- US$4.59B
- Quarter change
- +US$705.55M
- Entries
- 41
- Net bought (estimate)
- −US$11.31M
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 6
- Sold out 3
- Cut 2
- Added 8
- Corporate actions 0
- Unchanged 25
Largest holdings
41 stocks worth US$4.59B, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| MIRUM PHARMACEUTICALS INCCOM | Unchanged | 7,679,684 | US$899.06M | 19.58% |
| NAMSNEWAMSTERDAM PHARMA COMPANYORDINARY SHARES | Added | 18,088,902 | US$613.03M | 13.35% |
| ERASCA INCCOM | Added | 24,975,188 | US$457.55M | 9.96% |
| MBX BIOSCIENCES INCCOM | Unchanged | 6,652,013 | US$367.19M | 8.00% |
| ARCUTIS BIOTHERAPEUTICS INCCOM | Unchanged | 9,874,511 | US$258.91M | 5.64% |
| TREVI THERAPEUTICS INCCOM | Cut | 9,939,447 | US$185.37M | 4.04% |
| KRYSKRYSTAL BIOTECH INCCOM | Unchanged | 481,307 | US$178.89M | 3.90% |
| MAZEMAZE THERAPEUTICS INCCOM | Added | 5,032,915 | US$150.18M | 3.27% |
| PHATHOM PHARMACEUTICALS INCCOM | Unchanged | 12,466,489 | US$135.26M | 2.95% |
| PALVELLA THERAPEUTICS INC NECOM | Unchanged | 882,400 | US$134.85M | 2.94% |
Sign in (free) to see its 41 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 14, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.